Abstract:Background Puerarin (Pue) is an isoflavone compound with significant therapeutic effect on cardiovascular diseases, but its poor water solubility and low oral bioavailability limit clinical application. Methods In this study, Pue was prepared into PLGA nanoparticles (Pue-PLGA NPs) by emulsion solvent volatilization method. The morphology, particle size, Zeta potential, X-ray diffraction (XRD), and fourier transform infrared (FTIR) of the NPs were characterized. Additionally, their stability and in vitro release were evaluated. SD rats were orally administered wtih Pue and Pue-PLGA NPs, and a high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was established to determine the concentration of blood samples and to investigate the pharmacokinetic behaviour of Pue and Pue-PLGA NPs in rats. Results The NPs were observed by transmission electron microscopy (TEM) as regular spheroids and uniformly dispersed. The average particle size of the NPs was (167.1±5.26）nm, the Zeta potential was (-29.88±2.46)mV, the encapsulation rate was (83.12 %±4.73 %) and the drug loading capacity was (7.75 %±1.81 %). The results of in vitro release showed that the drug was released slowly and continuously from the NPs, reaching the release platform in 24 h, and the cumulative release amount was (88.55±2.86) %. The pharmacokinetic results showed that the AUC0–24, AUC0-∞, Cmax, Tmax, t1/2, MRT0–24 and MRT0-∞ of Pue-PLGA NPs were 2.196, 1.978, 1.327, 1.5, 1.385, 3.915 and 3.140 times of Pue, respectively. The relative bioavailability was (197.82±25.28) %. Conclusion These results indicated that the prepared nanoparticles had small particle size, high encapsulation rate, drug loading capacity and good slow-release effect, and could significantly improve the oral bioavailability of Pue in rats.

Study on Preparation of Puerarin Proliposomes and Its Pharmaceutical Characteristics in Vitro

Quality Evaluation of Puerarin Proliposomes

Preparation of Liposomes Encapsulating Puerarin-Cyclodextrin Complexes and Its Pharmaceutical Characteristics in Vitro

Preparation of puerarin solid lipid nanoparticles for oral administration

[Preparation and Characterization of Chitosan Coated Puerarin Liposomes].

Preparation of Puerarin Liposomes for Injection and Determination of Its Entrapment Efficiency

Study on Pharmacokinetics and Relative Bioavailability of Puerarin Proliposomes

Preparation and in Vitro Release Evaluation of Puerarin Sustained-Release Tablet

Preparation and Release Rate in Vitro of Puerarin Enteric Nanoparticles

Preparation and Characterization of Puerarin-Loaded Lipid Nanocapsules

Determination of Entrapment Efficiency of Puerarin Long Circulating Liposome by HPLC

A Study on the Preparation of Tanshinone Proliposomes

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Study on the Formulation Optimization and Drug Release in Vitro of Two-Layer Controlled Osmotic-Pump Tablets of Puerarin

[Formulation Optimization and Drug Release in Vitro of Membrane Controlled Tablets of Puerarin Inclusion Compound].

Preparation and Characterization of Puerarin-Phospholipid Complex

Preparation of oxaliplatin liposome and in vitro drug-release

The Study to Reduce the Hemolysis Side Effect of Puerarin by a Submicron Emulsion Delivery System

Poly (ethylene glycol) prodrug for puerarin and its characteristic evaluation

Preparation of Puerarin Chitosan Nanoparticles

Preparation and in vitro evaluation of gastroretentive dosage form containing puerarin-HP-β-CD inclusion complex